Key result
This review summarizes available treatment options for non-dystrophic myotonia and structure-activity relationship studies of new Nav1.4 channel blockers with potential antimyotonic activity.
Why the study?
Current sodium channel blockers for myotonia, such as mexiletine, are not selective for the Nav1.4 skeletal muscle isoform, highlighting the need to understand molecular requirements for more potent and use-dependent Nav1.4-targeting drugs.
This review highlights the need for more potent and selective Nav1.4 channel blockers for the treatment of non-dystrophic myotonia.
May inform selective Nav1.4 blocker design for non-dystrophic myotonia; leaves open clinical validation of efficacy and safety.
The voltage-gated sodium channels represent an important target for drug discovery since a large number of physiological processes are regulated by these channels. In several excitability disorders, including epilepsy, cardiac arrhythmias, chronic pain, and non-dystrophic myotonia, blockers of voltage-gated sodium channels are clinically used. Myotonia is a skeletal muscle condition characterized by the over-excitability of the sarcolemma, resulting in delayed relaxation after contraction and muscle stiffness. The therapeutic management of this disorder relies on mexiletine and other sodium channel blockers, which are not selective for the Nav1.4 skeletal muscle sodium channel isoform. Hence, the importance of deepening the knowledge of molecular requirements for developing more potent and use-dependent drugs acting on Nav1.4. Here, we review the available treatment options for non-dystrophic myotonia and the structure–activity relationship studies performed in our laboratory with a focus on new compounds with potential antimyotonic activity.
No takes yet. Share an insight, caveat, or question.
Bellis et al. (2023) conducted a review in Non-dystrophic myotonia. Nav1.4 channel blockers was evaluated. This review summarizes available treatment options for non-dystrophic myotonia and structure-activity relationship studies of new Nav1.4 channel blockers with potential antimyotonic activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: